StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Siddharth Rai Mangala

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

bySiddharth Rai MangalaHorizon: NA (inferred Intraday)6 Oct 2026, 9:25 am ISTvia Zee Business (Live)

Entry₹1,151.5Inferred
Target₹1,172
Total upside +1.78% (call closed)
Stop loss₹1,138-1.17% risk
At expiry₹1,163.36 Oct 2026, 3:05 pm
Expired+1.02%
Follow Siddharth Rai Mangala for new calls(13% target hit, 98 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 6 Oct, 4:21 pm IST
2 supporting1 neutral0 opposing
Supports the BUY call (2)

Zydus Lifesciences and MSN have partnered to launch the first generic version of Adempas (Riociguat tablets) in the U.S. market.

BSE · Company Update·5 Oct · today

(opens in new tab)

4 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·6 Oct · today

Neutral / worth noting (1)

Zydus hits 52-week high, can the optimism continue?

NewsLivemint·29 Sept · 1w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Siddharth Rai Mangala

Every call and its outcome